Drug reference
Cenegermin is a recombinant form of human nerve growth factor which allows restoration of corneal integrity; endogenous human nerve growth factor is involved in the differentiation and maintenance of neurons.
PDF page 1250
Moderate or severe neurotrophic keratitis (specialist use only) ▶TO THE EYE ▶Adult: Apply 1 drop 6 times a day, to be applied every 2 hours, starting in the morning and completing within 12 hours; treatment should be continued for 8 weeks
PDF page 1250
Eye infection—resolve before initiating treatment (if an infection occurs during treatment, cenegermin should be suspended until infection resolution). patients requiring immediate corneal surgery (assess for risk of corneal melting or impending perforation before initiating treatment)
PDF page 1250
Ocular cancer—manufacturer recommends monitor for cancer progression before and after treatment Children under 3 months owing to the possible association between cycloplegia and the development of amblyopia. darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage. mydriasis can precipitate acute angle- closure glaucoma (usually in those aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber) (in adults). mydriasis can precipitate acute angle-closure glaucoma (usually in those who are predisposed to the condition because of a shallow anterior chamber) (in children). neonates at increased risk of systemic toxicity (in neonates)
PDF pages 1250, 1251
NICE decisions ▶Cenegermin for treating neurotrophic keratitis (July 2018) NICE TA532 Cenegermin (Oxervate ®) is not recommended, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta532
PDF page 1251
▶Common or very common Eye discomfort. eye disorders. eye inflammation. headache. photophobia ▶Uncommon Corneal abscess ▶Frequency not known Eye haemorrhage Dizziness. photophobia. skin reactions. tachycardia
PDF pages 1250, 1251
Manufacturer advises avoid—no information available.
PDF page 1250
Manufacturer advises avoid—no information available.
PDF page 1250
Manufacturer advises that other topical ophthalmic preparations should be administered at least 15 minutes before or after use. l HANDLING AND STORAGE For information on storage of cenegermin, consult product literature.
PDF page 1250
No licensed medicines listed. 1.2a Anterior uveitis ANTIMUSCARINICS Antimuscarinics (eye) f
PDF page 1251
Manufacturer advises patients and carers should be counselled on how to administer cenegermin eye drops. Patients may not be able to undertake skilled tasks until vision clears after mydriasis. eiiii F above
PDF pages 1250, 1251
Apply 1 drop 6 times a day, to be applied every
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1250
